Could an Immune-Boosting drug ease autism symptoms?

NCT ID NCT07589842

Not yet recruiting Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a low-dose immune drug called interleukin-2 (ILT-101) in 22 children aged 6 to 8 with moderate to severe autism whose mothers had an autoimmune condition during pregnancy. The goal is to see if the drug can increase helpful immune cells (Tregs) and improve social and behavioral symptoms. The study compares the drug to a placebo over 6 months of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ILT-101 (low-dose interleukin-2)
What this could lead to: If it works, this could point toward a new treatment that improves social and behavioral symptoms in some children with autism.
What could go wrong: This is a very small, early-phase trial with only 22 children. It may not show clear benefits, and the treatment could cause side effects like injection reactions or immune changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism spectrum disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTISM SPECTRUM DISORDER

Contacts and locations

Locations

Robert Debré Hospital

Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.